Sarepta Therapeutics | SRPT - Equity Capital And Reserves


Sarepta Therapeutics reported $1.32B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Capricor Therapeutics USD 83.87M 21.11M Sep/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Moderna USD 8.65B 680M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novavax USD -156.67M 194.3M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Tectonic Therapeutic USD 267.53M 16.24M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025